CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more here.
Doctors harvest stem cells from the patient’s bone marrow and then send them off to a lab, where CRISPR is used to turn up the production of another, functional version of haemoglobin. This version is ...
Hosted on MSN1mon
Intellia Loses 21.6% in a Week: How Should You Play the Stock?Intellia is a clinical-stage gene editing company focused on developing innovative CRISPR-based therapies ... thereby preventing the production of TTR protein for the treatment of transthyretin ...
The data with the CRISPR/Cas9 drug CTX001 is still very early-stage, coming from just seven ... a gene known as BCL11A which down-regulates the production of the adult form of the oxygen-carrying ...
This injection must be timed just right such that it coincides with egg production, when large amounts of yolk proteins are incorporated into the eggs, the researchers found. “[T]he components of the ...
A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...
Intellia Therapeutics, Inc. is a clinical stage genome editing ... using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback